UCB looks expensive against a cash‑flow based estimate and what similar drugmakers suggest, but the gap sits inside a wide range where small long‑term assumptions can swing the outcome. The big question is how much confidence you can place in far‑future growth and the drug pipeline when most of today’s “value” comes from years beyond the near term.Read more

KBC’s value looks very different depending on whether you focus on the cash it plans to return to shareholders or the strength of its balance sheet. The big question is whether today’s generous payouts can hold up if the bank’s risk profile and loan losses move back toward more typical levels.Read more

SIPEF is riding a lift in palm oil and banana output while benefiting from stronger demand tied to biofuels, and it’s backing that up with a solid cash position and investments in cleaner operations. The big watch‑outs are political and trade shocks, tricky weather, and rising costs that could squeeze results if conditions turn.Read more

NAV As Sofina is an investment holding company, NAV is an important factor in my evaluation. This Net Asset Value is estimated at a price share of 297 Eur, up from 294 last year.Read more